Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday.
The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use.
The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said.
In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease.
Related articles:
Related suggestion:
Here's where Biden and Trump stand on 10 key issuesPWHL's strong first season coincides with a growing appetite for women's sportsHappy birthday Archie! As the young royal turns five todayChina's trade with other BRICS members up 11.3 pct in Q1Sports betting roundup: Betting the under works in hockey Game 7s while basketball goes overEdward Olivares' grand slam and Mitch Keller's complete game lead Pirates over Angels 4Boeing calls off Starliner launch due to rocket issueBank holiday booze76ers president Daryl Morey has big plans to build NBA title team around Embiid and MaxeyDonald Trump calls Joe Biden weak on antisemitism, ignoring his own rhetoric
0.128s , 5118.296875 kb
Copyright © 2024 Powered by Medicare can pay for obesity drugs like Wegovy in certain heart patients ,International Illustrations news portal